▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cardiff Oncology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.15.
The current consensus among 0 polled investment analysts is to n/a stock in Cardiff Oncology. This rating has held steady since January 2021, when it changed from a Buy consensus rating.
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.